
    
      This is a prospective, single-arm, multicenter, open-label clinical trial in which
      participants will use the Oculeve Intranasal Lacrimal Neurostimulator to stimulate tear
      production for 180 days. Participants will have a Screening Visit within 60 days prior to the
      initial device application. Device application will be initiated at Day 0, at which time
      participants will receive training on the proper use of the device. Participants will receive
      follow-up visits at Days 7, 30, 90 and 180.
    
  